# Andy Derr Foundation for Kidney Cancer Research

Grantmaking public charity, Fogelsville, Pennsylvania. EIN 81-1302321.

Source: the foundation’s own IRS returns, read November 20, 2026, as shown by the Alleviate Index. https://sites.alleviate.org/index/funder/andy-derr-foundation-for-kidney-cancer-research-811302321

## Applications

Schedule I of Form 990 lists the grants made, not how to apply, so this return does not say whether Andy Derr Foundation for Kidney Cancer Research accepts applications.

## What it gave

- Grants paid: $75,000 (Year ending December 2025)
- Grants listed: 2 (To organizations, on that return)
- Typical grant: $37,500 (Half fall between $31,250 and $43,750)

- December 2025: Grants paid $75,000; Grants listed 2
- December 2024: Grants paid $55,176; Grants listed 2

From Schedule I of its Form 990 returns for the years ending December 2024 to December 2025.

## What it funds, and where

- Focus, by share of linked grant dollars: None of its grants could be linked to a charity with certainty, so no focus is shown.
- Where it gave, by number of grants: Pennsylvania 4

## Recent grants to organizations

- LEHIGH VALLEY HEALTH NETWORK (Allentown, Pennsylvania): $50,000, year ending December 2025. FUNDING WAS PROVIDED TO THE LEHIGH VALLEY HEALTH NETWORK FOR A NUMBER OF ITS CANCER INSTITUTE'S 2025 AND 2026 INITIATIVES.
- ST LUKES HOSPITAL (Bethlehem, Pennsylvania): $25,000, year ending December 2025. FUNDING TO ST LUKE'S UNIVERSITY HEALTH NETWORK WAS FOR THE SECOND YEAR OF THE TWO-YEAR IMMUNE GENE MUTATION RESEARCH PROJECT THAT EXPLORES HOW GENETIC MUTATIONS, SUCH AS BETA-2 MICROGLOBULIN (B2M), AFFECT PATIENT RESPONSE TO IMMUNOTHERAPY IN KIDNEY CANCER. IN ADDITION, THE FUNDS SPONSORED SLUHN'S CONFERENCE ATTENDANCE FOR RESEARCHERS.
- LEHIGH VALLEY HEALTH NETWORK (Allentown, Pennsylvania): $30,176, year ending December 2024. FUNDING WAS PROVIDED TO THE LEHIGH VALLEY HEALTH NETWORK FOR A NUMBER OF ITS CANCER INSTITUTE'S 2024 AND 2025 INITIATIVES.
- ST LUKES HOSPITAL (Bethlehem, Pennsylvania): $25,000, year ending December 2024. FUNDING TO ST LUKE'S UNIVERSITY HEALTH NETWORK WAS FOR A TWO-YEAR IMMUNE GENE MUTATION RESEARCH PROJECT THAT EXPLORES HOW GENETIC MUTATIONS, SUCH AS BETA-2 MICROGLOBULIN (B2M), AFFECT PATIENT RESPONSE TO IMMUNOTHERAPY IN KIDNEY CANCER. OUR SUPPORT NOT ONLY DRIVES CUTTING-EDGE RESEARCH AND DATA ANALYSIS BUT ALSO DEVELOPS FUTURE ONCOLOGY LEADERS THROUGH MENTORSHIP, CONFERENCE PARTICIPATION, AND PUBLICATION OPPORTUNITIES.

Method and sources: https://sites.alleviate.org/index/method#funders
